WO2001011366A1 - Antigenic components of selected indicator fungi and their use in methods and test kits - Google Patents
Antigenic components of selected indicator fungi and their use in methods and test kits Download PDFInfo
- Publication number
- WO2001011366A1 WO2001011366A1 PCT/FI2000/000668 FI0000668W WO0111366A1 WO 2001011366 A1 WO2001011366 A1 WO 2001011366A1 FI 0000668 W FI0000668 W FI 0000668W WO 0111366 A1 WO0111366 A1 WO 0111366A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fungi
- indicator
- antigenic
- indicator fungi
- components
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56961—Plant cells or fungi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
- C07K14/38—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from Aspergillus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/37—Assays involving biological materials from specific organisms or of a specific nature from fungi
- G01N2333/38—Assays involving biological materials from specific organisms or of a specific nature from fungi from Aspergillus
Definitions
- the present invention is related to antigenic components specific for three toxigenic indicator fungi, Stachybotrys chartarum, Aspergillus versicolor and Memnoniella echinata and having substantially no cross-reactivity with other fungi. Also disclosed are their use for producing binding substances and manufacturing test kits for determining the presence or absence of said toxigemc fungi and for screening the quality and extent of fungal contamination, the remedial measures needed as well as for controlling whether the applied measures have been sufficient and effective. Also described is the use of the antigenic components for screening whether a person has been exposed to the selected indicator fungi and/or has a link between the exposure and allergic responses.
- An easy on-the-site method would enable development of standards for evaluation of fungal contamination.
- the method and test kit would allow easy checking that the standards are followed. They would also enable evaluation of economical damages caused by improper conditions and would be advantageous for checking the effect of remedial measures by screening whether the applied remedial measures have been successful in removing hazardous or irritating fungal components.
- cultivation methods have been used for detecting fungi in contaminated materials and in the air of problem buildings.
- cultivation methods are often too slow, particularly in cases, wherein prompt decisions are needed for choosing the most appropriate remedial measures to remove contaminants from the building.
- only viable fungal particles can be detected with the cultivation methods and it is well-known that only 1 - 25 % of the airborne fungal spores are viable. In the case of Stachybotrys, only 10 % of spores present in the air have been assumed to be viable and detectable with the cultivation methods.
- Immunochemical test strips have been suggested as a solution to the problem in field situations. Test strips would provide sufficient accuracy for practical use to detect the presence of Stachybotrys or other selected indicator fungi in different samples from various surroundings. They would not require any expensive equipment or special expertise for use. In fact, some commercial products and/or tests based on immunochemical applications are available for certain mycotoxins, but so far no products have been developed, which could specifically detect and differentiate the defined indicator fungi from other fungi. Toxins are not the product of choice for determination because all Stachybotrys, Memnoniella or A.
- the desired fungal product for determination should not be limited to stachybotryotoxins, but should enable the identification of the whole organism, e.g. a Stachybotrys species, instead of stachybotryotoxins.
- test strips or test sticks comprising the test kits of the present invention provide a solution to the above-identified problem by providing immunochemical methods and test kits, which are sufficiently specific, selective and rapid.
- the test kits are capable of specifically recognizing one or more antigenic components from defined potentially dangerous indicator fungi, either separately, one by one or in any combination, either consecutively or simultaneously, from the same sample source.
- the methods and test kits allow an effective, rapid assessment of the quality and extent of contamination and evaluation of possible health risks, need of remedial measures, etc.
- the objectives of the present invention is to provide improved methods for detecting, controlling the presence of detrimental fungal growth and evaluating possible health risks caused by indicator fungi and thereby to prevent certain fungi from growing by applying appropriate remedies.
- Another objective of the present invention is to provide means for carrying out said method.
- the means comprise specific antigenic or allergenic fungal components originating from the defined indicator fungi as well as binding substances or other materials selectively recognizing said antigenic fungal components.
- the present inventions provides a solution to the problems listed above by providing new methods for detecting fungal contamination of certain type.
- the method and the products and means utilized in said method are as defined in the claims of the present invention.
- Figure 1 shows SDS-Page profiles of the S. chartarum (A), M. echinata (B) and A. versicolor (C) extracts.
- Figure 2 shows the components of the S. chartarum (A), M. echinata (B) and A. versicolor extracts recognized by the S. chartarum -specific rabbit antisera.
- Figure 3 depicts immunoblottings of different S. chartarum preparations Lane _ Untreated S. chartarum extract immunoblotted against S. chartarum-specific rabbit immune serum.
- Lane 2 Periodate-treated S. chartarum extract immunoblotted against S. c/t rt ⁇ rw -specific rabbit immune serum. Removal of carbohydrates influenced antibody binding to the 18, 19, 32, 36 and 41 kDa components.
- the terms used have the meaning they generally have in the fields of human and veterinary medicine and diagnostics, especially in on-the-site diagnostics, mycology, toxicology, immunology as well as in immunochemistry. Some terms, however, are used with a somewhat deviating or broader meaning in this context. Accordingly, in order to avoid uncertainty caused by terms with unclear meaning some of the terms used in this specification and in the claims are defined in more detail below.
- evaluating means judging or assessing from recorded, measurable or visually detectable results, the quality and extent of fungal contamination and whether the remedial measures have been successful.
- evaluation is based on the determination, measurement or detection of antigenic or allergenic components of certain indicator fungi using "binding substances” specifically recognizing and binding to said "antigenic components”.
- the term "environmental sample” means a subsample of material or dust from the environment suspected of being contaminated with fungi. Such subsamples are obtainable or collectable from building materials, constructions, accumulated dust, bedding materials, fodder, foodstuffs, etc. The subsamples should be representative, i.e. they should describe the damaged or contaminated area sufficiently well.
- the term "specifically recognizing and binding” means that the substance used to detect the defined fungal contaminant, the so called indicator fungus, detects components specific for the indicator fungi, but not other fungal components which are common to most fungi.
- indicator fungi means certain toxigenic fungi with verified health detrimental effects, which have been selected for the present invention based on their health detrimental qualities and their capacity of producing toxins. The presence of “indicator fungi” indicates that remedial measures are urgently needed in order to avoid health risks.
- the most preferred “indicator fungi” selected for the purpose of the present invention are selected from the genera Stachybotrys, Aspergillus and Memnoniella and especially including the toxigenic species: Stachybotrys chartarum, Aspergillus versicolor and Memnoniella echinata.
- non-indicator fungi means other fungi, which are ubiquitously present, but which are not toxigenic to the same extent as “the indicator fungi” of the present invention. They cannot be considered to cause an extreme health hazard. If “non-indicator fungi” were detected, they would cause false alarms, which is not desired in order to avoid unnecessary, generally very expensive special remedial measures and protective measures, while the remedial actions are carried out.
- the contamination with non-indicator fungi naturally leads to some remedial actions, but those actions are not extremely urgent and extensive. For example, they do not require special protection measures against exposure among repair men and occupants during remedial activities as in the case of contamination by toxigenic indicator fungi.
- cross-reactivity means that an antibody is able to bind to an antigen that did not originally elicit production of said antibodies.
- Fungal species of the same genus have been reported to cross-react in various degrees.
- cross-reactivity has also been observed between species of different fungal genera.
- One reason for the cross-reactivity is that the extracts of different fungal species can contain same or similar allergenic or immunogenic components or unspecific binding occurs between the glycoproteins, polysaccharides and the antibodies.
- the term "devoid of cross-reactivity” means that the selected antibody or binding substance elicited by the antigenic component or binding specifically to the antigenic compound does not recognize and bind to non-indicator fungi, but only recognizes the indicator fungi. In other words it is specific solely for the indicator fungi.
- selection means that a certain component with desired properties, e.g. specificity and/ or devoid of cross-reactivity is chosen by isolation from a large group of antigenic components, the properties, e.g. cross-reactivities of which have been compared with the properties or cross-reactivities of other fungi.
- the term “manufacturing” means the production of "antigenic components” with desired properties by isolation, purification, characterization and selection by conventional methods and thereafter by per se known recombinant DNA techniques.
- the term also include the preparation of "binding substance” specifically recognizing and/or binding to said "antigenic components” and their use for preparing “binding substances” by conventional immunotechnical methods, hybridoma techniques and recombinant DNA techniques.
- Said “antigenic components” and “binding substances” can be used for production of the test kits in methods for determining the absence or presence of indicator fungi and assessing the quality and extent of the fungal contamination.
- Preparations or compositions, comprising the components useful as "antigenic components” can be prepared by isolation and purification methods such as chromatography purification system, gel filtration chromatography, anion exchange chromatography, cation exchange chromatography, reversed phase chromatography, affinity chromatography, e.g. lektin columns, etc.
- the components obtained can be characterized by SDS-PAGE, Western blotting, etc. and the cross-reactivity can be tested by per se known methods.
- the term "quality of fungal contamination” means that the fungal contamination is severe, e.g. because of a high probability that toxic components are present and said toxic components or contamination has a clear health risk causing impact on those exposed in the vicinity of the contamination. Generally, special and urgent remedial measures, such as extensive repair, sanitary and protective measures are required.
- the term "extent of fungal contamination” means the area contaminated with health detrimental fungi and also indicates how widely spread or how large and grave the moisture and consequent fungal contamination damages are.
- diagnosis means that the environmental consults, physicians, veterinarians, etc. decide based on results obtained with a specific immunoassay method or test kit if a person has been exposed to contamination of indicator fungi and/or if there is a link between the exposure and allergic responses. In such cases the presence of antibodies in serum samples obtained from the person suspected of fungal exposure is a confirmatory result for exposure of indicator fungi, whereas the absence of antibodies means that no exposure is likely.
- direct means includes such immunoassays in which agglutination of the antigenic components happens in presence of the corresponding antibodies.
- the agglutination can be recorded, either visually or spectrophotometrically, as the turbidity developed during the reaction. In other words it means that only antigen and antibody is required, whereas the term “indirect means” indicates that the binding substances, i.e. antibodies or the antigenic components are made detectable by providing them with suitable markers or labels, such as latex particles, metal alloys, liposomes, enzymes, fluo- rochromes, etc.
- antigenic components means immunogenic components of fungal origin, which are capable of eliciting antibodies against said components.
- antigenic components in its broadest aspect in the present invention, covers not only allergenic components, but also components which are typical and/or specific for certain indicator fungi, preferably any antigenic fungal components which do not cross-react with antigenic components from other so called “non-indicator fungi”.
- antigenic component comprises components obtainable from antigenic preparations of Aspergillus versicolor, Stachybotrys chartarum and Memnoniella echinata, which have been shown to correlate well with the quality of fungal contamination.
- binding substances including binding proteins or peptides as well as antibodies, which specifically recognize the antigenic components of said indicator fungi.
- binding substance which recognize indicator fungi in its broadest aspect means any substances capable of specifically recognizing and binding at least one, preferably more antigenic components or at least a part therof. Such substances are, for example, receptors or binding proteins or binding peptides, capable of specifically binding antigenic components and not cross-reacting with others. Above all binding substances mean antibodies capable of specifically recognizing one or more antigenic compositions of the three indicator fungi of the present invention, either separately or in any combination.
- the antibodies include both polyclonal and/or monoclonal antibodies as well as fragments or derivatives thereof.
- the prerequisite being that the "binding substances” specifically recognize at least one of the above-defined antigenic components and does not cross-react with others.
- Said “binding substances” can be developed using any of the “antigenic components” of the present invention, as well as their fragments, derivatives and complexes, the only prerequisite being that the "antigenic components” are capable of acting as “antigens", i.e. eliciting antibodies.
- binding substances refers to any compositions or materials capable of eliciting an antibody response specific to said antigenic components or compositions or materials containing them.
- Said antibodies are producible by conventional techniques for producing polyclonal antibodies as well as monoclonal antibodies.
- the methods for preparing monoclonal antibodies include hybridoma techniques. Fragments of antibodies or other binding molecules or compounds like specific binding peptides can be developed by phage display techniques and produced by recombinant DNA techniques. All methods are well known by those skilled in the art and described in laboratory handbooks. The most recent techmques include development of synthetic polymer binding substances.
- immunoassay refers to a ligand-binding assay that uses a specific antigen and/or antibody capable of binding to said antigene or analyte, i.e. to methods or procedures capable of detecting and/or measuring the "antigenic components" from the three indicator fungi, wherein the active and specific reagents include at least one antibody or part thereof capable of specifically binding said "antigemc components".
- Immunoassay principles can also be used in detecting antibodies against fungal antigens in patient sera. These antibodies are measured by their specific binding to the corresponding fungal antigenic components.
- immunoassays are radio- immunoassays (RIA), radioimmunometric assays (IRMA), fluoroimmunometric assays (IFMA) enzyme immunoassays (El A), enzyme-linked immunosorbent assays (ELISA), fluoroimmmunoassays (FLA), luminescence immunoassays, immunoagglutination assays, turbidimetric immunoassays, nephelometric immunoassays, etc. All methods are well known by those skilled in the art and described in laboratory handbooks. Basic types of immunoassays include above all "sandwich assays", which are defined below.
- sandwich assay refers to an assay in which one antibody (or antigen molecule) is used to capture the analyte of interest, while another (often with different specificity) is used for detection.
- “Sandwich assay” also refers to an immunoassay using chemical or immunochemical binding of the analyte to a solid phase and the immunochemical binding of the analyte to a solid phase and the immunochemical binding of a second (labeled) reagent to the analyte.
- sandwich assay refers to an immunoassay using at least two antibodies or one antibody and one antigen capable of detecting or quantifying the amount of antibody or antigen in a sample. For example, two different antibodies capable of binding two different, non-overlapping (non-competitive) epitopes on the antigen can for example be used. Different types of "sandwich assays" exist as described below.
- the term “Lateral Flow Technique” refers to an immunoassay using immunochromato- graphic principles. It is typical for the test that the sample or test solution, which is in liquid form moves along a test strip in contrast to the "Flow-Through Technique” in which the test solution is allowed to flow through a membrane in a test device.
- Flow Through Technique refers to an immunoassay often based on the sandwich technique.
- the antigen containing sample or test solution is applied as a spot and is allowed to diffuse through a membrane in a device.
- On-the-site assay means a test which can be performed in the field or in the actual place of contamination. It does not require transport of the samples and refers to tests or procedures performed without any laboratory facilities and without the need of qualified laboratory personnel. The term corresponds to the term "bed-side assay” used in hospitals and health care institutions. "On-the-site assay” means tests made by environmental consultants, industrial hygienists, health inspectors or other responsible professionals under field conditions. Also included are so called “self-tests”, where the tests can be carried out by the those occupying the contaminated building. "On-the-site assays" are preferably performed on “solid carriers” like test strips. Various allergenic components can be detected simultaneously on the same strip or stick.
- fungi of the genus Stachybotrys e.g. S. chartarum
- other fungi such as Memnoniella echinata and Aspergillus versicolor
- trichothecenes by Stachybotrys and Memnoniella as well as sterigmatocystin by A. versicolor Intensive production of trichothecenes has been observed, particularly, on moist high-cellulose and low-nitrogen materials, e.g. on wallpaper, gypsum board, in hay and straw.
- Ingestion of contaminated feed is the main exposure route for mycotoxins in animals.
- Symptoms of animal toxicosis after exposure to either trichothecenes or A.versicolor toxins include, toxic irritation of eyes, skin, and mucous membranes followed by necrosis, changes in blood parameters, hemorrhages as well as teratogenic and carcinogenic effects in many organs (especially in kidney and liver), severe disorders of the immune system including teratogenic and carcinogenic effects depending on the toxin dose.
- handling of contaminated materials and inhalation of airborne toxins containing spores are the most potential routes of exposure.
- the risk of exposure to toxins is essential among farmers and those occupying and/or repairing buildings with contamination of the toxigenic indicator fungi.
- Acute symptoms of human toxicosis comprise several toxic, irritative and nonspecific symptoms, such as dermatitis, cough, rhinitis, burning sensations in the mouth and nasal passages, sore throat, fever, headache, diarrhea, feebleness, and fatigue, possibly painful, severe pharyngitis, and a burning sensation in the nose, and bloody nasal exudates.
- toxicosis in humans exposed by inhalation are still unknown. Due to its health detrimental properties, Stachybotrys and A. versicolor have been named two of the most important indicator micro-organisms for moisture and/ or health problems in buildings by indoor air experts.
- Stachybotrys chartarum is probably the most dangerous fungus in buildings with moisture problems, indicating advanced moisture damages and serious health implications for occupants of the affected buildings.
- Memnoniella echinata is associated with the presence of Stachybotrys chartarum in contaminated materials.
- Pure cultures of M. echinata has also been indicated to produce similar or same toxins as S. chartarum.
- this fungus is a subject of intensive research and it will probably be included as one of the most hazardous fungi in the future.
- the present inventors chose Stachybotrys as the key indicator fungi for their studies, but also the other fungi, especially of the genus Memnoniella as well as species Aspergillus versicolor are applicable as useful indicator fungi. It was shown that unspecified determination of breakdown and/or toxic products of the indicator fungi was not satisfactory especially because of their cross-reactivity with break-down products of other ubiquitously present but less health detrimental non-indicator fungi and certain insecurity related to mycotoxin analyses.
- the cross-reactivity between the different fungal species may be due to the same or similar antigenic components, for example enzymes, that are shared by several fungi. Also, carbohydrate components of the glycoproteins may cause unspecific cross-reactivity (Brouwer, J. 1996, Int. Arch. Allergy Immunol. Vol. 110: 166-173; Nissen, D. et al. 1998, Ann. Allergy Asthma Immunol. Vol. 81: 247-255).
- Stachybotrys chartarum was grown in artificial malt extract broth and in cellulose broth that simulates its natural cellulose-rich growth media.
- Stachybotrys chartarum The cross-reactivity between Stachybotrys chartarum and 10 fungal species (Alternaria alternata, Aspergillus versicolor, Aureobasidium pullulans, Chaetomium globosum, Cladosporium cladosporioides , Memnoniella echinata, Penicillium brevicompactum, Phialophora rebens, Phoma sp. and Ulocladium botrytis) was studied by the inhibition immunoblotting method.
- the present inventors studied the cross-reactivity between the selected indicator fungi and other common fungi not included in the group of toxigenic indicator fungi as defined in the present invention (Table 1 and Table 2). Based on the results obtained, they identified specific antigenic components which do not significantly cross-react with other ubiquitous fungi. Based on said selected antigenic components the inventors have been able to produce specific binding substances, e.g. monoclonal antibodies, which are capable of identifying one or more specific antigenic components originating from one or more of the indicator fungi and capable of differentiating between different kinds of fungal contamination.
- specific binding substances e.g. monoclonal antibodies
- Said antigenic components and their specific binding substances are not only capable of recording the absence or presence of certain indicator fungi but are optimal for determining the quality, severity and extent of fungal contamination. They also overcome the cross-reactivity problems discussed above. In the studies extracts of S. chartarum, A. versicolor and Memnoniella were shown to contain several antigenic components.
- the glycoproteins of S. chartarum -extract were obtained by Boehringer-Mannheim DIG Glycan Differentation Kit. The most abundant carbohydrate in the S. chartarum -extract was mannose. The carbohydrate moiety was present in components with the molecular weight of 30 kD or higher. The significance of the carbohydrate content of S. chartarum glycoproteins for the antibody binding activity was demonstrated by periodate treatment of S. chartarum -extract (removing sugars), followed by immunoblotting with the S. chartarum specific rabbit antisera (Example 5). These results were compared to the immunoblotting results of native (no periodate treatment) S. chartarum -extract. These results showed that the removal of carbohydrate moieties from S. chartarum extract partially decreased the binding of S. chartarum specific rabbit immune serum to components in the extract, except for the 27 and 50 kDa components, which remains unchanged.
- the antibodies produced can optionally be tagged with a label or marker molecule capable of making the presence or absence of the indicator fungi alone or in any combination recordable.
- a label or marker molecule capable of making the presence or absence of the indicator fungi alone or in any combination recordable.
- Various labels, markers or tags, also called tracer when combined with the antibodies or respective antigens are known and described in literature, laboratory handbooks and patent publications.
- Such labels or markers are, for example, coloured latex particles, fluorochromes, liposomes, metal colloids, etc. However, it is to be noted that it is not necessary to use such labels and markers.
- polyclonal antibodies as such are used and when they bind to the antigen the sample solution gets turbid. The turbidity is caused by antibody-antigen-aggregates forming during the reaction. Said aggregates can be detected visually.
- the antigenic fungal components which allow the specific differentiation of various defined contaminants and which are most suited and effective, for the desired, specific, diagnostic purpose, were selected. Said antigenic fungal components were used to develop test kits and methods targeted to diagnose the quality and extent of fungal contamination.
- the present invention provides a highly effective diagnostic tool for evaluating the need and type of remedial measures in cases of fungal contamination.
- the methods and test kits provide effective means for follow-up studies and for monitoring the success of the remedial measures.
- the test could be used for self diagnostics, especially by environmental consultants, industrial hygienists, house sellers, buyers and builders as well as their health contentious clients.
- the invention disclosed in the present patent specification provides a highly effective diagnostic tool for an accurate evaluation of the kind of fungal contamination and measures needed to correct the situation.
- the method and kits of the present invention above all provide alternative on-the-site diagnostic tools for recording the presence or absence of certain indicator fungi and for evaluating the quality of the contamination.
- the method and test kit provides an effective and practical tool for follow up studies of the efficacy of remedial measures.
- Any immunochemical test methods can in principle be used for evaluating the quality of contamination as well as for longitudinal or latitudinal screening of the effects of remedial measures.
- visual agglutination, flow-through and immunochromatographic methods are best suited for rapid on-the-site tests. It is possible to prepare test sticks or test strips, which contain several different antibodies in separate zones and with which it is possible to detect several allergenic components simultaneously.
- the investigator carries out a test by placing an absorbing test strip or corresponding solid carrier directly in contact with a subsample obtained by removing a dry sample of material from the area suspected of being contaminated.
- the dry sample is transferred into a suitable liquid carrier, such as a buffer and is extracted to provide the subsample.
- the test strip is thereafter allowed to absorb liquid from the subsample extract, preferably for a standardized time.
- a dipstick-type test device can be so designed that it includes an absorbing end that is placed in contact with the sample source, which is absorbed directly into test device.
- Recombinant allergens can also be used for determining fungus specific antibodies in serum samples of human exposed to the indicator fungus.
- E.g. elevated levels of specific IgG indicate increased exposure to the indicator fungus and high levels of specific IgE refer to possible allergic responses against of the fungus.
- verified antigen components the antibody measurements become more reliable and accurate compared to the present techniques.
- the present invention is related to methods and test kits for determining the presence or absence of the defined indicator fungi or their antigenic components in environmental samples and for evaluating the quality and extent of fungal contamination in sick and moisture damaged buildings, houses, factories, agricultural environments and other working environments, for evaluating the need and urgency of remedial and protective measures to avoid health risks caused by fungal contamination, for targeting remedial measures to reduce and/or eliminate contamination and for evaluating whether the applied measures have been successful.
- the diagnosis should be perform- able as a rapid and reliable on-the-site assay using one or more binding substances capable of specifically recognizing one or more specific antigenic components originating from the defined indicator fungi, e.g. Stachybotrys alone or in combination with some other indicator fungi in environmental samples.
- the indicator fungi Stachybotrys chartarum (strain ATCC 208877) was isolated from gypsum board derived from a moisture damaged building in 1991. The strain was identified at Centraalbureau voor Scbimmelcultures (CBS), Baarn, the Netherlands.
- CBS Centraalbureau voor Scbimmelcultures
- the fungal species were first allowed to grow on an artificial 2% Malt extract agar for 7-10 days at 25 °C, after which spore suspensions were prepared in phosphate-buffered saline (PBS) with 0.05% (v/v) Tween 20.
- PBS phosphate-buffered saline
- One ml of the spore suspension was inoculated in 100 ml of 2% Malt extract broth in stationary Roux bottles and the cultures were incubated for 10 days at 25 °C.
- Example 1 Fungal species mentioned in Example 1 were allowed to grow as described in Example 1 in cellulose containing liquid broth (Dillon, H. K., Heinsohn, P. A. , Miller, J. D. (eds), Field Guide for the Determination of Biological Contaminants in Environmental Samples. AIHA Publications, Fairfax, Virginia 1996) that simulates the natural growing media (straw, gypsum board) of S. chartarum.
- cellulose containing liquid broth Dillon, H. K., Heinsohn, P. A. , Miller, J. D. (eds), Field Guide for the Determination of Biological Contaminants in Environmental Samples. AIHA Publications, Fairfax, Virginia 1996) that simulates the natural growing media (straw, gypsum board) of S. chartarum.
- the membrane strips were incubated overnight with pooled terminal rabbit antisera at a dilution of 1:5000 and thereafter with per ⁇ xidase-conjugated swine anti-rabbit immunoglobulins at a dilution of 1:5000 for 1 h. All the incubations were at room temperature. Strips were washed with PBS-Tween several times. The autoradiographic reaction was developed by ECL -Western blotting reagents and the immunologically reactive protein components were detected by autoradiography film. In the inhibition-immunoblotting analysis used in cross-reactivity testing, the S. chartarumlA. versicolor-spccific antiserum was first incubated at 37 °C for 1 h with several dilutions of the other fungal extracts. Thereafter, the analyses were completed as described before.
- the S. chartarum -extract prepared from the culture grown in cellulose broth revealed more protein components (13) than the extract prepared from the culture grown in malt extract broth (12).
- the extract prepared from malt extract broth contained non-immunogenic components with a small-molecular weight that caused intense smearing of the coomassie-stained SDS-PAGE gel.
- the extract prepared from cellulose broth revealed also more immunogenic components in the immunoblotting analysis (18) than the other extract (12).
- the components of about 92, 57 and 25 kD gave the most intensive reactions, while the components of about 60, 50, and 31 reacted strongly with the rabbit antiserum in the extract prepared from cellulose broth.
- A. versicolor extract prepared from fungi cultured in cellulose broth revealed 18 protein components of which the components of about 100, 98, 85, 55 and 43 kD were the most abundant (Fig. 1).
- the rabbit antisera raised against A. versicolor cultured in malt extract broth recognized distinctly the components of about 125, 110, 98, 82, 62, 55, 50, 43, 37, 36, 32 and 29 kD in the A. versicolor extract prepared from fungi cultured in cellulose extract.
- chartarum extract The lowest protein concentration (2 ⁇ g/ml) of the S. chartarum extract prepared from the culture grown in malt extract broth used for the inhibition prevented the visualization of 45 % , and the extract prepared from the culture grown in cellulose broth 65% of its components.
- the fungal species that are morphologically closely related to S. chartarum (A. alternata, M. echinata and U. botrytis ) cross-reacted more intensively with it than the other fungi.
- chartarum -specific antibodies was easily inhibited by the other fungal preparations, were those of about 67, 31, 20 and 17 kD, while the binding was difficult to inhibit to components of about 77, 64, 57 and 25 kD. Binding of the S. chartarum-specific antibodies was easily inhibited to the components below 50 kD by the other fungal preparations, while the binding was difficult to inhibit to the components of about 60 and 50 kD. The five other strains of S. chartarum tested inhibited strongly the binding of the S. chartarum -specific rabbit antise- rum to the components of S. chartarum in the immunoblotting analyses indicating similar antigenic components.
- the rabbit antisera raised against A. versicolor cultured in malt extract broth recognized distinctly 11 components in the S. chartarum extract cultured in cellulose broth.
- the rabbit antisera raised against S. chartarum cultured in cellulose broth recognized distinctly one component (60 kD) in the A. versicolor extract cultured in cellulose broth (Fig. 2).
- the figure was 6 components (150, 110, 60, 38, 37 and 32 kD) (Fig.2).
- the components of about 60 and 50 kDa proved to be the most specific for S. chartarum cultured in cellulose broth in the inhibition-immunoblotting studies (Table 1).
- the 50 kDa component may be shared between M. echinata and S. chartarum, but the fact that the rabbit antisera raised against S. chartarum cultured in cellulose broth recognized only very faintly the component of 50 kD in the M. echinata extract may refer to the fact that the cross-reactivity may possess an unspecific nature.
- the glycoproteins of Stachybotrys chartarum -extract were determined by Boehring- er-Mannheim DIG Glycan Differentation Kit. The most abundant carbohydrate in the S. chartarum-extr&ct was mannose. Other carbohydrates, for example galactose- ⁇ (l-4)-N-acetylglucosamine and sialic acid were also identified. The carbohydrate moiety was present in most components with the molecular weight of 30 kD or higher. The significance of the carbohydrate content of S. chartarum glycoproteins for the antibody binding activity was demonstrated by periodate treatment of S. chartarum -extract (removing sugars), followed by immunoblotting with the S. chartarum specific rabbit antisera (Example 5).
- At least one hour treatment with 50 mM Na-periodate at dark was needed to remove the sugar moiety from the mold-extract.
- the effectiveness of the periodate treatment was performed by further glycoprotein analysis with Boehringer-Mannheim DIG Glycan Differentation Kit. Sugars (mannose, galactose- ⁇ (l-4)-N-acetylglucosamine and sialic acid) identified in native S. chartarum extract could not be identified after periodate treatment.
- N-glycosidase-enzyme F endoglycosidase-enzyme was used for hydrolyzation of all types of N-glycan chains from glycoproteins (removing sugars). After treatment, the molecular size of the 50 kDa component remains unchanged, while most of the other components in the S. chartarum-exiract profile (SDS-page) were either disappeared or the molecular size was changed (reduced) as a sign of removed carbohydrate content.
- the frozen samples were re-suspended in PBS (pH 7.4) and dialyzed (molecular weight cut-off 8 kD) against three changes of PBS at 4°C. Max 250 ⁇ l samples of mold-extract were injected to the superdex 75 HR 10/30 column (Pharmacia Biotech, Uppsala, Sweden). PBS (pH 7.4) was used as an eluent. All peaks were collected, starting from the first peak, equilibrated with the same buffer.
- the frozen samples were re-suspended in PBS (pH 7.6) and dialyzed (molecular weight cut-off 8 kD) against three changes of 20 mM Tris (pH 7.6) at 4°C.
- Max 2ml samples of mold-extract in 20 mM Tris (pH 7.6) were injected to the Resource Q HR 5/5 column (Pharmacia Biotech, Uppsala, Sweden) equilibrated with the same buffer.
- the bounded proteins were eluated with linear 90 ml gradient from 0 to 1 M NaCl in 20 mM Tris (pH 7.6) and all peaks were collected.
- the frozen samples were re-suspended samples in 20 mM citric acid (pH 2.7) and dialyzed (molecular weight cut-off 8 kD) against three changes of 20 mM citric acid at 4°C.
- Max 2ml samples of mold-extract in 20 mM citric acid (pH 2.7) were injected to the Resource S HR 5/5 column (Pharmacia Biotech, Uppsala, Sweden) equilibrated with the same buffer.
- the bound proteins are eluated with a linear 90 ml gradient from 0 to 1 M NaCl in 20 mM citric acid (pH 2.7) and all peaks were collected.
- SDS-PAGE Sodium dodecyl sulphate - polyacrylamide gel electrophoresis
- the proteins from SDS-PAGE gel were transferred to polyvinylidene difluoride membrane (Immobilon-P, Millipore) at 100V for 30 min.
- the membrane was stained with 0.1 % Coomassie brilliant blue and destained with 50 % methanol. Stained 50 kD band was excised with a scalpel and they were allowed to dry at room temperature.
- Dried gel slices were swollen partly with 10 ⁇ l of 100 mM ammonium hydrogen carbonate buffer containing 10% acetonitrile and 0.5 ⁇ g TPCK treated trypsin (Sigma). 100 mM Tris-HCl buffer, pH 9.2, 10% acetonitrile was added slowly to cover the gel slices, and the incubation was carried out overnight.
- the peptides were extracted twice at 37 °C in a shaker with 60% acetonitrile - 0.1% TFA. The digestion solutions were pooled together and dried to a about 50 ⁇ l volume.
- RP-HPLC reverse-phase high-performance liquid chromatography
- TFA trifluoroacetic acid
- Applied Biosystems 477 A Pulsed Liquid Phase protein sequencer was used to determine amino acid sequences of the peptides.
- the cDNA library was immunoscreened using sera of patients with proved S. chartarum exposure histories and typical clinical symptoms of S. chartarum exposure or sensitiza- tion.
- the cDNA library was also immuno screened with the S. chartarum specific rabbit anti-sera (Example 5). Phage plaques were lifted onto isopropylthio- ⁇ -D-galactoside -treated nitrocellulose filters (Amersham). Filters were washed, blocked by 0.1 % casein in phosphate-buffered saline (PBS, pH 7.4) for four hours and further incubated with the 1 :5 diluted human or 1:50 diluted rabbit anti-sera.
- PBS phosphate-buffered saline
- HRP-labelled 1 10 diluted anti-human IgE (DAKO, P0295) and HRP-labelled 1:5000 diluted anti-rabbit Ig (DAKO, P0399) were used as secondary antibodies with a four hours incubation. Filter washings and serum and conjugate dilutions were made in PBS with 0.1 % Tween. All incubations and washings were made at room temperature with gently agitation. The autoradio- graphic reaction was developed by ECL- Western blotting reagents (Amersham) and the immunologically reactive plaques were detected by autoradiography film (Amersham). Positive plaques were picked and purified with repeated phage dilutions and immunoblot- tings.
- the amino acid sequence produced by sequencing of the internal peptides was used as a model for planning PCR-primers for cDNA library screening.
- Peptide MLNVYFYGH (SEQ ID NO: l:) was used for producing degenerated PCR-primers.
- the other PCR-primers were planned for pBluescript SK(+/-) phagemid cloning vector.
- the upper strain primers were T3 primer AATTAACCCTCACTAAAGGG (SEQ ID NO:2:) and peptide based GTYCCNATYAAYATYCANCTY (SEQ ID NO:3:).
- the lower strain primers were T7 primer CGGGATATCAGTCAGCATAATG (SEQ ID NO:4:) and peptide based GAYGTNAYTTYTAYGGNCAY (SEQ ID NO:5:).
- A is adenine
- C is cytosine
- G is guanine
- T is thymine
- Y means both C + T and N codes all A + C + G + T.
- 32p-labelled oligonucleotide probes were designed from the DNA sequence produced by PCR-amplification (described above) and cDNA library was screened according to the standard protocol of Sambrook, J. et al. (Molecular Cloning, A laboratory Manual. Cold Spring Harbor, New York, 1989)
- PCR-products were isolated from agarose gel and purified by GELase* 311 Agarose Gel-Digesting Preparation method (Epicentre technologies) before DNA sequencing (described above).
- cDNA of S. chartarum (UKU 10) was used as a template for PCR.
- the primers were designed to include the leader sequence of specific S. chartarum protein as well as Eco Rl sites for cloning in the pHIL-D2 expression vector of Pichia pastoris (Invitrogen, Leek, the Netherlands).
- the other primers were designed for cloning in the pHIL-Sl expression vector of Pichia pastoris.
- the plasmid construction was performed with standard techmques (Invitrogen), and the correct insertion into the plasmid was verified by sequencing.
- the recombinant plasmid was transformed in Pichia pastoris strain GS115 (Invitrogen) by lithium chloride transformation method.
- Seed cultures of transformed Pichia yeast were grown in a salt-based medium (BMG; Invitrogen) containing 1.0 % (v/v) glycerol on a rotating incubator at 30 °C.
- BMG salt-based medium
- yeast cells were collected by centrifugation and resuspended in one-fifth of the same medium base without glycerol, methanol was added to 0.5 % (v/v) and the incubation continued for 6 days with daily adding of methanol.
- the supernatants of the cultures were harvested by centrifugation and the recombinant protein was purified with a procedure comprising affinity chromatography, ion exchange chromatography and gel filtration chromatography.
- Stachybotrys chartarum specific antigens isolated and purified as mentioned in Examples 10 and 14 were prepared essentially as described in Example 3, beginning from the step of vacuum drying.
- mice were immunized three times ititraperitoneally with 100 g S. chartarum specific antigen at two weeks intervals. Freud's complete adjuvant was used for the first injection and Freud's incomplete adjuvant for the second injection. The last injection was given without adjuvant, and the mice were sacrificed four days later, monoclonal antibodies were produced according to Galfre, G. , et al., Nature 266:550-552 (1977)). Spleen cells of immunized mice were fused with the NSI-1 mouse myeloma cell line using 50 % polyethylene glycol (MW 1500). Hybridomas were tested for antibody production with ELISA and immunoblotting methods and selected hybridomas were cloned twice by the limiting dilution method.
- a narrow zone of a nitrocellulose strip (strip 1 , approximately 6 x 25 mm) is coated with a monoclonal antibody against specific components of Stachybotrys chartarum. Coloured latex particles are coated with another antibody against the same component.
- the coated latex particles are dried on a zone in the middle of a strip of absorbing polyethylene material (STRIP 2). The diameter of the latex particles is small enough that they could flow freely through the pores in both strip materials.
- the two strips are attached on a plastic backing so that they are in a contact which allows capillary flow of sample liquid from strip 2 to strip 1 when the end of strip 2 is dipped into liquid. For absorption of excess liquid, a pad of filter paper is attached in contact with strip 1 opposite to strip 2.
- the dipstick constructed is used to perform the rapid indicator fungus component test according to the following instructions.
- Example 19 The collection and preparation of environmental samples is very simple. An investigator evaluates and recognizes suitable sites of sampling that represent contaminated area sufficiently well, a subsample is taken from a sampling site (building material, other substrate, accumulated dust, etc) and is transferred into a test tube containing buffer solution and shaken carefully. A dip-stick is placed into the buffer and the instruction in Example 19 is followed.
- samples from pure cultures of various Stachybotrys chartarum strains and other indicator fungal strains and other common non-indicator fungal species as well as mixed cultures of the indicator and other fungi and contaminated environmental samples are prepared artificially with known fungal species and collected from filed conditions.
- Example 17 The samples obtained as described in Example 17 are diluted in buffer (PBS containing Tween 20 and aprotinin (50 klU/ml), pH 7,4)
- One end of the dipstick (end of strip 2) is dipped into the diluted sample and kept there until the liquid front reaches strip 1, and is then removed from the sample.
- Strip 1 is inspected. Already a minimal amount of S. chartarum components will cause a visible line. If a coloured zone is formed, the result is interpreted as positive.
- Stachybotrys chartarum + + + + - + + ++ ++ ++ ++ +++
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
Abstract
Description
Claims
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU64455/00A AU6445500A (en) | 1999-08-05 | 2000-08-04 | Antigenic components of selected indicator fungi and their use in methods and test kits |
| JP2001515971A JP2003506099A (en) | 1999-08-05 | 2000-08-04 | Antigenic components of selected indicator fungi and methods of using the antigenic components in test kits |
| EP00951558A EP1206701A1 (en) | 1999-08-05 | 2000-08-04 | Antigenic components of selected indicator fungi and their use in methods and test kits |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI991675 | 1999-08-05 | ||
| FI19991675 | 1999-08-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2001011366A1 true WO2001011366A1 (en) | 2001-02-15 |
Family
ID=8555121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/FI2000/000668 Ceased WO2001011366A1 (en) | 1999-08-05 | 2000-08-04 | Antigenic components of selected indicator fungi and their use in methods and test kits |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1206701A1 (en) |
| JP (1) | JP2003506099A (en) |
| AU (1) | AU6445500A (en) |
| WO (1) | WO2001011366A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003016352A1 (en) * | 2001-08-10 | 2003-02-27 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Monoclonal antibodies against fungi and methods for their use |
| WO2022221177A1 (en) * | 2021-04-11 | 2022-10-20 | Khurana Vikas | Diagnosis and treatment of congestive colon failure (ccf) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4845197A (en) * | 1985-09-09 | 1989-07-04 | Agri-Diagnostics Associates | Monoclonal antibodies and methods for fungal pathogen detection |
| WO1998046738A1 (en) * | 1997-04-15 | 1998-10-22 | Barnes-Jewish Hospital | Methods of obtaining antigens specific for fungi, antibodies for such antigens, and diagnosis of disease using such antigens and/or antibodies |
-
2000
- 2000-08-04 EP EP00951558A patent/EP1206701A1/en not_active Withdrawn
- 2000-08-04 AU AU64455/00A patent/AU6445500A/en not_active Abandoned
- 2000-08-04 WO PCT/FI2000/000668 patent/WO2001011366A1/en not_active Ceased
- 2000-08-04 JP JP2001515971A patent/JP2003506099A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4845197A (en) * | 1985-09-09 | 1989-07-04 | Agri-Diagnostics Associates | Monoclonal antibodies and methods for fungal pathogen detection |
| WO1998046738A1 (en) * | 1997-04-15 | 1998-10-22 | Barnes-Jewish Hospital | Methods of obtaining antigens specific for fungi, antibodies for such antigens, and diagnosis of disease using such antigens and/or antibodies |
Non-Patent Citations (2)
| Title |
|---|
| DATABASE BIOSIS [online] REED JON A. ET AL.: "Immunomycology: Rapid and specific immunocytochemical identification of fungi in formalin-fixed, paraffin-embedded material", XP002909875, Database accession no. PREV199396076781 * |
| JOURNAL OF HISTOCHEMISTRY AND CYTOCHEMISTRY, vol. 41, 1993, pages 1217 - 1221 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003016352A1 (en) * | 2001-08-10 | 2003-02-27 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Monoclonal antibodies against fungi and methods for their use |
| US7368256B2 (en) | 2001-08-10 | 2008-05-06 | United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Antibodies against Stachybotrys chartarum and methods for their use |
| WO2022221177A1 (en) * | 2021-04-11 | 2022-10-20 | Khurana Vikas | Diagnosis and treatment of congestive colon failure (ccf) |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2003506099A (en) | 2003-02-18 |
| AU6445500A (en) | 2001-03-05 |
| EP1206701A1 (en) | 2002-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chu et al. | Indirect enzyme-linked immunosorbent assay for saxitoxin in shellfish | |
| Kwaasi et al. | Aeroallergens and viable microbes in sandstorm dust: Potential triggers of allergic and nonallergic respiratory ailments | |
| Adams et al. | Development and use of monoclonal antibody probes forimmunohistochemistry, ELISA and IFAT to detect bacterial and parasitic fish pathogens | |
| Camargo et al. | Monoclonal antibody capture enzyme immunoassay for detection of Paracoccidioides brasiliensis antibodies in paracoccidioidomycosis | |
| Banowetz et al. | Immunological comparisons of teliospores of two wheat bunt fungi, Tilletia species, using monoclonal antibodies and antisera | |
| Magnadóttir et al. | A comparison of total and specific immunoglobulin levels in healthy Atlantic salmon (Salmo salar L.) and in salmon naturally infected with Aeromonas salmonicida subsp. achromogenes | |
| Silva et al. | Heterologous antibodies to evaluate the kinetics of the humoral immune response in dogs experimentally infected with Toxoplasma gondii RH strain | |
| CN109709339A (en) | Colloidal gold immunochromatographic test strip for detecting bovine or sheep skeletal muscle troponin I and its application | |
| Matthews et al. | Characterisation and cellular localisation of the immunodominant 47-Kda antigen of Candida albicans | |
| Rajeshwari et al. | Development of ELISA for the detection of Ralstonia solanacearum in tomato: its application in seed health testing | |
| Saulnier et al. | Antigenic and biochemical study of PKX, the myxosporean causative agent of proliferative kidney disease of salmonid fish | |
| AU616384B2 (en) | Method for the evaluation of oral microbes | |
| Bisht et al. | Antigenic and allergenic cross-reactivity of Epicoccum nigrum with other fungi | |
| Ismail et al. | A competitive immunosorbent assay for detection of Pseudomonas pseudomallei exotoxin | |
| El-Nashaar et al. | Enzyme-Linked Immunosorbent Assay Quantification of Initial Infection of Wheat by Gaeumannomyces graminis var. tritici | |
| Priestley et al. | Development of a monoclonal antibody immunoassay for the eyespot pathogen Pseudocercosporella herpotrichoides | |
| Nigam et al. | A new glycoprotein allergen/antigen with the protease activity from Aspergillus fumigatus | |
| EP1206701A1 (en) | Antigenic components of selected indicator fungi and their use in methods and test kits | |
| CN109810191A (en) | A kind of anti-sheep skeletal muscle troponin I monoclonal antibody and its application | |
| CN109705216A (en) | A kind of anti-bovine skeletal muscle troponin I monoclonal antibody and its application | |
| CA1285222C (en) | Monoclonal antibodies useful in the identification of microorganisms causing periodontal disease | |
| Verma et al. | Studies on shared antigenic/allergenic components among fungi | |
| JP2007527523A (en) | Reagent, method and kit for detecting feed enzymes | |
| Karmakar et al. | Isolation and characterization of two IgE-reactive proteins from Azadirachta indica pollen | |
| Wilson et al. | Comparison of partially purified mycelial and culture filtrate antigens of Aspergillus fumigatus by enzyme-linked immunosorbent assay |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2000951558 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 10049254 Country of ref document: US |
|
| WWP | Wipo information: published in national office |
Ref document number: 2000951558 Country of ref document: EP |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 2000951558 Country of ref document: EP |